AAAbdulelah Almutairdi

Abdulelah Almutairdi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdulelah Almutairdi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and Impact of Zinc Deficiency on Clinical Outcomes in Inflammatory Bowel Disease

    by Hend Almuhaya, Raghad Alsalamah, Asma Sallam, Amgad Alonazy, Atheer AlAwwad, Gamal Mohamed, Abdulelah Almutairdi, Mashary Attamimi, Badr Al-Bawardy

    Background: Inflammatory bowel disease (IBD) can lead to zinc deficiency, which plays a critical role in immune function and tissue repair. This study aims to determine the prevalence, clinical characteristics, and impact of zinc deficiency in IBD patients. Methods: This is a retrospective study of patients aged ≥14 years with confirmed IBD and available zinc level measurement. Zinc deficiency was defined as a level p < 0.001) levels, and were more likely to be on corticosteroids (p = 0.04). Zinc deficiency was associated with higher rates of IBD-related hospitalizations (48.0% vs. 17.7%), surgeries (19.6% vs. 5.8%), complications (30.4% vs. 12.4%), and emergency room visits (40.2% vs. 17.3%) (all p < 0.001). Upon multivariate analysis, predictors of IBD-related hospitalization were zinc deficiency (OR 2.42, 95% CI 1.07–5.48, p = 0.03) and low albumin (OR 9.03, 95% CI 3.38–24.15, p < 0.001). Zinc deficiency was associated with IBD-related surgeries (OR 5.23, 95% CI 1.27–21.45, p = 0.02) and complications (OR 3.98, 95% CI 1.52–10.41, p = 0.005). Conclusions: Zinc deficiency is prevalent in patients with IBD, associated with a high inflammatory burden, and was linked to worse clinical outcomes after controlling for markers of inflammation.


  • Open Access

    Mapping the Ulcerative Colitis Patient Journey in Saudi Arabia from Healthcare Professionals’ Perspective: A Cross-Sectional Non-Interventional Study

    by Nahla Azzam, Mahmoud Mosli, Abdulelah Almutairdi, Mesfer Alghamdi, Yaser Meeralam, Khalid Alolimi, Mohammad Arsalan, Badr Al-Bawardy

    Background/Objectives: The burden of ulcerative colitis (UC) is increasing in Saudi Arabia (KSA), and patients with UC often suffer from delays in diagnosis and appropriate management. This study investigates the current UC patient journey in KSA from the healthcare professionals’ (HCPs) perspective. It aims to evaluate treatment patterns, identify critical gaps, and provide insights to guide interventions that enhance the quality of life for UC patients in KSA. Methods: Quantitative interviews were conducted with 60 HCPs (45 gastroenterologists and 15 internal medicine specialists) from different regions in Saudi Arabia (KSA) using a Computer-Assisted Personal Interview (CAPI) system. The survey domains included clinical symptoms, diagnostic testing, endoscopic scoring, treatment goals, and medication sequencing. Results: Data were collected from 60 HCPs with an average of 17 ± 12.5 years of experience. Most patients with UC were referred by general practitioners (28%), internal medicine physicians (25%), followed by surgeons (16%). The first-ranked treatment goals were clinical remission (53.3%), endoscopic remission (35%), and improvement of quality of life (33.3%). For outpatient moderate-to-severe UC, the most common first-line treatments are oral systemic steroids (34%), 5-aminosalicylates (5-ASAs) (26%), and TNF-α inhibitors (21%). While second-line treatment rankings were TNF-α inhibitors (23%), followed by Interleukin 12/23 inhibitors (19%), and Janus kinase (JAK) inhibitors (14%). Sphingosine 1-phosphate (S1P) receptor modulators are not well-utilized due to a lack of availability (88%), unfamiliarity with the treatment (24%), and formulary exclusion (12%). Conclusions: In conclusion, most UC patients are referred by general practitioners. Treating gastroenterologists prioritize clinical remission as a treatment goal. Corticosteroids remain overutilized as reflected by treating physicians’ responses. The underutilization of advanced therapies underscores the need for enhanced education and improved access to integrate emerging therapies effectively.

  • Open Access

    Colorectal Neoplasia in Inflammatory Bowel Disease

    by Eman Al Sulais, Turki AlAmeel, Maram Alenzi, Mohammad Shehab, Abdulelah AlMutairdi, Badr Al-Bawardy

    Patients with inflammatory bowel disease (IBD), including ulcerative colitis and colonic Crohn’s disease, are at an increased risk of developing colonic dysplasia and neoplasia. Multiple risk factors have been identified that increase the risk of colonic neoplasia in IBD, including but not limited to underlying disease extent, severity, duration, and concomitant primary sclerosing cholangitis. The overall risk of colonic neoplasia in IBD is decreasing but surveillance is still warranted in patients with high-risk features. In this review, we will discuss the epidemiology, pathogenesis, risk factors, approach to surveillance, and management of colonic neoplasia in IBD.


  • Open Access

    Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus

    by Sameer Al Awadhi, Mohamed Alboraie, Emad Aldin Albaba, Abdulelah Almutairdi, Monther Alsaad, Nahla Azzam, Husam Barakat, Ferdinando D’amico, Silvio Danese, Mohamed El Kady, et al.

    The prevalence of ulcerative colitis (UC) in the Middle East is increasing, impacting the economic and healthcare burden. The management of patients with mild to moderate UC is still a challenge as several factors can affect optimal care, including drug choice, induction and maintenance dose, treatment optimization and de-escalation, therapy duration, monitoring, and safety profile. We conducted an expert consensus to standardize the management of patients with mild to moderate UC. Sixteen experts in inflammatory bowel diseases, through a well-established and accepted Delphi methodology, voted and approved eight statements in order to provide practical guidance to clinicians in the Middle East.